Prof Isabella Ray-Coquard speaks to ecancer at ESMO 2019 in Barcelona about the PAOLA-1/ENGOT-ov25 Phase III trial, which showed the benefits of treating advanced ovarian cancer patients with bevacizumab and PARP inhibitor olaparib in the first-line setting.
She explains that this intensive regimen was given to patients both with and without a BRCA mutation. While both groups were found to have extended progression-free survival, this was more pronounced in the subgroup of patients with BRCA mutations and those with homologous recombination deficiency (HRD).
Prof Ray-Coquard comments that these results suggest a new first-line standard of care for patients with advanced ovarian cancer, but she adds that the ability to test patients to determine their outcomes is an important aspect of providing this treatment.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.